Press Release

Biohaven’s FGFR3 ADC Shows First Objective Response in Its Class Worldwide
2026.07.21

Clinical Benefit in Both Mutant and Overexpressing Tumors… Dose-Limiting Toxicity Not Reached; Additional Data to Be Presented at ESMO




 

According to a recent press release from Biohaven, the Phase 1 trial of AMB302 (BHV-1530), an FGFR3-targeting ADC licensed from Aimedbio, has shown objective responses, including confirmed partial responses, across multiple patients and tumor types.
 

Notably, BHV-1530 showed clinical activity not only in tumors with FGFR3 alterations but also in tumors overexpressing wild-type FGFR3. Unlike existing FGFR small-molecule inhibitors, which mainly target patients with FGFR alterations, this suggests that treatment could extend to overexpressing patients. This is seen as substantially broadening the addressable patient population and market potential.
 

BHV-1530 is continuing dose escalation in the Phase 1 trial and has not yet reached the dose-limiting toxicity (DLT) level. The major class toxicities known from existing FGFR inhibitors have also not been observed to date. Biohaven plans to presentd clinical data at ESMO 2026 this October.
 

Biohaven has also signed a clinical supply agreement with Regeneron. It plans to begin a combination trial of BHV-1530 with Libtayo, Regeneron’s PD-1 immunotherapy, in the second half of this year, to evaluate the potential for further efficacy gains. 

 

By contrast, Lilly’s FGFR3 ADC, LY3076226, showed no objective responses among 25 patients in its Phase 1 trial. BHV-1530, in comparison, has produced objective responses in multiple patients, giving the first concrete sign of the clinical potential of FGFR3 ADCs.